ACOR: Summary for Acorda Therapeutics, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, November 25, 2009, 2:42pm EST - Canadian Markets close in 1 hour and 18 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Acorda Therapeutics, Inc. (ACOR)

At 14:27 EST: 24.49 USD

0.19 (0.78%)

MORE ON ACOR

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Acorda Therapeutics, Inc. (NGM:ACOR) Delayed quote data

Last Trade:	24.49 USD
Trade Time:	2:27PM EST
Change:	0.19 (0.78%)
Prev Close:	24.30
Open:	24.54
Bid:	24.48 x 1100
Ask:	24.49 x 200
1y Target Est:	30.00

Day's Range:	24.29 - 24.58
52wk Range:	14.89 - 29.27
Volume:	226,606
Avg Vol (3m):	1,105,570
Market Cap:	933.56M
P/E (ttm):	N/A
EPS (ttm):	-2.17
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y

Add ACOR to Portfolio

Download Data

HEADLINES

•	Acorda Therapeutics to Present at the 21st Annual Piper Jaffray Health Care Conference
	Business Wire (Tue 7:00am)

•	Acorda Therapeutics to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
	Business Wire (Mon, Nov 16)

•	Abbott: Brave or Stupid?
	at Motley Fool (Fri, Nov 13)

•	ACORDA THERAPEUTICS INC Financials
	EDGAR Online Financials (Wed, Nov 11)

•	Big Pharma & Biotech
	Zacks.com (Tue, Nov 10)

•	Big Pharma and Biotech
	Zacks.com (Mon, Nov 9)

•	ACORDA THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report
	EDGAR Online (Fri, Nov 6)

•	Zacks Bull and Bear of the Day Highlights: Acorda Therapeutics, Canon, Big Lots, Wal-Mart and Nordstrom
	Zacks.com (Fri, Nov 6)

•	Acorda Therapeutics (ACOR)
	Zacks.com (Fri, Nov 6)

•	New Star Analyst Rankings for Acorda Therapeutics, Inc.
	StarMine (Wed, Nov 4)

•	A Little Distracted, Are You, Merck?
	at Motley Fool (Tue, Nov 3)

•	Acorda Therapeutics 3Q loss widens on costs
	AP (Tue, Nov 3)

•	Acorda Therapeutics Earnings Call scheduled for 8:30 am ET today
	CCBN (Tue, Nov 3)

•	Q3 2009 Acorda Therapeutics Earnings Release - Before Market Open
	CCBN (Tue, Nov 3)

More Headlines for ACOR...

ANALYST

EPS Est (next year) (Dec-09) :	-2.22
EPS Est (in 2 years) (Dec-10) :	-1.68
Avg Rec (current)*:	1.9
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Acorda Therapeutics, Inc., a biopharmaceutical company, engages in the identification, development, and commercialization of various therapies for the improvement of neurological functions in people with multiple sclerosis (MS), spinal cord injury...

Full Company Profile

Add to Portfolio

Email to a Friend

•